Payment overview · 2025
General Payments
$99.76
6 reported records · 3 companies
Healthcare provider profile · identity verified
Whitney Bonner Sparks, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BELMONT, MS · NPI 1265865992
Verified facts
What the public records show
CMS Open Payments records show Whitney Bonner Sparks, NP received $99.76 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.48 | 54.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.47 | 28.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.81 | 16.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $99.76 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.48 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.47 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 64 |
| Gabapentin | Gabapentin | 234 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 204 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 42 |
| Metformin Hcl Er | Metformin Hcl | 161 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 34 |
| Lisinopril | Lisinopril | 159 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 56 |
| Omeprazole | Omeprazole | 155 | 45 |
| Montelukast Sodium | Montelukast Sodium | 146 | 39 |
| Famotidine | Famotidine | 144 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 42 |
| Ezetimibe | Ezetimibe | 126 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 31 |
| Furosemide | Furosemide | 125 | 28 |
| Buspirone Hcl | Buspirone Hcl | 123 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 30 |
| Losartan Potassium | Losartan Potassium | 113 | 33 |
| Pregabalin | Pregabalin | 106 | 12 |
| Potassium Chloride | Potassium Chloride | 101 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 23 |
| Ozempic | Semaglutide | 90 | 20 |
| Trazodone Hcl | Trazodone Hcl | 88 | 28 |
| Carvedilol | Carvedilol | 77 | 18 |
| Donepezil Hcl | Donepezil Hcl | 75 | 17 |
| Simvastatin | Simvastatin | 73 | 14 |
| Mounjaro | Tirzepatide | 69 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 25 |
| Meloxicam | Meloxicam | 67 | 27 |
| Clonazepam | Clonazepam | 63 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 14 |
| Jardiance | Empagliflozin | 58 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 12 |
| Sertraline Hcl | Sertraline Hcl | 56 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | 11 |
| Fluconazole | Fluconazole | 51 | 31 |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Febuxostat | Febuxostat | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 13 |
| Ondansetron Odt | Ondansetron | 45 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 14 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 38 |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Metformin Hcl | Metformin Hcl | 43 | 15 |
| Vraylar | Cariprazine Hcl | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Eliquis | Apixaban | 39 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 11 |
| Nystatin | Nystatin | 39 | 17 |
| Allopurinol | Allopurinol | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 16 |
| Methocarbamol | Methocarbamol | 34 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 19 |
| Cefdinir | Cefdinir | 29 | 26 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Prednisone | Prednisone | 24 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 18 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $99.76 · 6 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error